×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
NASDAQ:VCYT

Veracyte Stock Forecast, Price & News

$23.93
+0.52 (+2.22%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$23.19
$24.25
50-Day Range
$15.45
$23.93
52-Week Range
$14.85
$54.13
Volume
1.18 million shs
Average Volume
959,332 shs
Market Capitalization
$1.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.14

Veracyte MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
76.1% Upside
$42.14 Price Target
Short Interest
Healthy
11.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.05
Upright™ Environmental Score
News Sentiment
0.66mentions of Veracyte in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$979,800 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.86) to ($0.57) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.95 out of 5 stars

Medical Sector

526th out of 1,433 stocks

Medical Laboratories Industry

13th out of 32 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

Veracyte logo

About Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT Stock News Headlines

Veracyte (NASDAQ:VCYT) Trading Up 6.2%
Veracyte (NASDAQ:VCYT) Shares Down 5.1%
Veracyte (NASDAQ:VCYT) Trading 7.2% Higher
Veracyte (NASDAQ:VCYT) Shares Gap Down on Insider Selling
Veracyte (NASDAQ:VCYT) Shares Up 6.8%
Veracyte (NASDAQ:VCYT) Trading Down 5.8%
See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCYT
Employees
761
Year Founded
N/A

Company Calendar

Last Earnings
5/03/2022
Today
7/06/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$42.14
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+76.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71428571428571
Research Coverage
7 Analysts

Profitability

Net Income
$-75,560,000.00
Pretax Margin
-20.13%

Debt

Sales & Book Value

Annual Sales
$219.51 million
Book Value
$15.43 per share

Miscellaneous

Free Float
69,373,000
Market Cap
$1.71 billion
Optionable
Optionable
Beta
0.98














Veracyte Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Veracyte stock.
View analyst ratings for Veracyte
or view top-rated stocks.

What is Veracyte's stock price forecast for 2022?

7 Wall Street analysts have issued 12 month price targets for Veracyte's stock. Their VCYT stock forecasts range from $26.00 to $59.00. On average, they expect Veracyte's stock price to reach $42.14 in the next twelve months. This suggests a possible upside of 76.1% from the stock's current price.
View analysts' price targets for Veracyte
or view top-rated stocks among Wall Street analysts.

How has Veracyte's stock price performed in 2022?

Veracyte's stock was trading at $41.20 at the beginning of the year. Since then, VCYT stock has decreased by 41.9% and is now trading at $23.93.
View the best growth stocks for 2022 here
.

When is Veracyte's next earnings date?

Veracyte is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Veracyte
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings results on Tuesday, May, 3rd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.03. The biotechnology company earned $67.78 million during the quarter, compared to analyst estimates of $61.98 million. Veracyte had a negative net margin of 19.22% and a negative trailing twelve-month return on equity of 4.09%. During the same quarter last year, the firm posted ($0.11) EPS.
View Veracyte's earnings history
.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $265.00 million-$275.00 million, compared to the consensus revenue estimate of $270.30 million.

Who are Veracyte's key executives?

Veracyte's management team includes the following people:
  • Ms. Bonnie H. Anderson, Co-Founder & Exec. Chairwoman (Age 64, Pay $1.21M) (LinkedIn Profile)
  • Mr. Marc A. Stapley, CEO & Director (Age 52, Pay $900.4k)
  • Ms. Rebecca Chambers, Exec. VP & CFO (Age 44, Pay $607.65k)
  • Dr. Giulia C. Kennedy Ph.D., Global Chief Scientific Officer & Chief Medical Officer (Age 63, Pay $691.33k)
  • Dr. Tina S. Nova Ph.D., Pres of CLIA U.S. Bus. (Age 68, Pay $4.58k)
  • Ms. Beverly Jane Alley CPA, VP & Corp. Controller (Age 59, Pay $398.01k)
  • Mr. Jonathan Wygant, VP & Chief Accounting Officer (Age 51)
  • Mr. William W. Zondler, Sr. VP & Chief Information Officer
  • Ms. Annie McGuire, Sr. VP & Gen. Counsel (Age 42)
  • Ms. Tracy Morris, VP of Global Corp. Communications

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

How do I buy shares of Veracyte?

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $23.93.

How much money does Veracyte make?

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.71 billion and generates $219.51 million in revenue each year. The biotechnology company earns $-75,560,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does Veracyte have?

Veracyte employs 761 workers across the globe.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for Veracyte is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.

This page (NASDAQ:VCYT) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.